New COVID-19 Variant PJ.2.1 Detected in Multiple Countries

A newly identified SARS-CoV-2 lineage known as PJ.2.1 has been found circulating in several countries, according to recent reports and genomic surveillance data.

The variant was first detected in Ontario, Canada, in May 2026. It has since been identified in the United States, parts of Europe, Singapore, Australia and New Zealand.

Early laboratory research published in the Journal of Infection indicates that PJ.2.1 may bind more efficiently to the human ACE2 receptor, which the virus uses to enter cells. This characteristic could support increased transmissibility compared with some earlier lineages. However, there is currently no evidence that the variant causes more severe illness or significantly reduces the effectiveness of existing vaccines against serious outcomes.

Public health experts and the World Health Organization are monitoring the lineage as part of routine surveillance of SARS-CoV-2 evolution. Authorities stress that PJ.2.1 is not a new pandemic virus or “COVID 2,” but another evolving Omicron-related strain. Symptoms appear similar to those of other recent COVID-19 variants or common respiratory illnesses such as influenza and the common cold.

Genomic data from Ontario showed the variant accounting for a rising share of sequenced cases in recent months, reaching around 25% in one surveillance period. Scientists continue to track its growth, immune evasion properties and clinical impact.